Is Immunitybio Stock a Good Investment?
Immunitybio Investment Advice | IBRX |
- Examine Immunitybio's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Immunitybio's leadership team and their track record. Good management can help Immunitybio navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Immunitybio's business and its evolving consumer preferences.
- Compare Immunitybio's performance and market position to its competitors. Analyze how Immunitybio is positioned in terms of product offerings, innovation, and market share.
- Check if Immunitybio pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Immunitybio's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Immunitybio stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Immunitybio is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Insignificant | Details | |
Volatility | Unstable | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Immunitybio Stock
Researching Immunitybio's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 74.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.57. Immunitybio had not issued any dividends in recent years.
To determine if Immunitybio is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Immunitybio's research are outlined below:
| Immunitybio had very high historical volatility over the last 90 days | |
| Immunitybio has a very high chance of going through financial distress in the upcoming years | |
| Immunitybio currently holds 504.17 M in liabilities. Immunitybio has a current ratio of 0.3, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Immunitybio's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 14.74 M. Net Loss for the year was (413.64 M) with profit before overhead, payroll, taxes, and interest of 31.16 M. | |
| Immunitybio currently holds about 82.94 M in cash with (391.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.21. | |
| Immunitybio has a frail financial position based on the latest SEC disclosures | |
| Roughly 74.0% of the company shares are held by company insiders | |
| Latest headline from gurufocus.com: Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635 IOVA ... |
Immunitybio Quarterly Cash And Short Term Investments |
|
Immunitybio uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Immunitybio. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Immunitybio's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of February 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Immunitybio's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Immunitybio's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-11-12 | 2021-09-30 | -0.2 | -0.22 | -0.02 | 10 | ||
2020-11-09 | 2020-09-30 | -0.18 | -0.2 | -0.02 | 11 | ||
2020-05-11 | 2020-03-31 | -0.17 | -0.19 | -0.02 | 11 | ||
2019-11-05 | 2019-09-30 | -0.18 | -0.16 | 0.02 | 11 | ||
2024-08-06 | 2024-06-30 | -0.17 | -0.2 | -0.03 | 17 | ||
2024-05-09 | 2024-03-31 | -0.16 | -0.2 | -0.04 | 25 | ||
2022-05-10 | 2022-03-31 | -0.22 | -0.26 | -0.04 | 18 | ||
2020-03-25 | 2019-12-31 | -0.2 | -0.16 | 0.04 | 20 |
Know Immunitybio's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Immunitybio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Immunitybio backward and forwards among themselves. Immunitybio's institutional investor refers to the entity that pools money to purchase Immunitybio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Charles Schwab Investment Management Inc | 2025-03-31 | 1.3 M | Goldman Sachs Group Inc | 2025-03-31 | 1.1 M | Jpmorgan Chase & Co | 2025-03-31 | 1 M | Bsc Private Wealth Management, Llc | 2025-03-31 | 846.4 K | Verition Fund Managegment, Llc | 2025-03-31 | 827 K | Susquehanna International Group, Llp | 2025-03-31 | 773.5 K | Allen Holding Inc | 2025-03-31 | 687.6 K | Sheets Smith Wealth Management | 2025-03-31 | 633.5 K | Accurate Wealth Management, Llc | 2025-03-31 | 560 K | Vanguard Group Inc | 2025-03-31 | 20.3 M | Blackrock Inc | 2025-03-31 | 13.3 M |
Immunitybio's market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.43 B.Market Cap |
|
Immunitybio's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.13) | (1.18) | |
| Return On Capital Employed | (1.05) | (1.10) | |
| Return On Assets | (1.08) | (1.13) | |
| Return On Equity | 0.85 | 0.89 |
Determining Immunitybio's profitability involves analyzing its financial statements and using various financial metrics to determine if Immunitybio is a good buy. For example, gross profit margin measures Immunitybio's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Immunitybio's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Immunitybio's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Immunitybio. Check Immunitybio's Beneish M Score to see the likelihood of Immunitybio's management manipulating its earnings.
Evaluate Immunitybio's management efficiency
Immunitybio has return on total asset (ROA) of (0.5562) % which means that it has lost $0.5562 on every $100 spent on assets. This is way below average. Immunitybio's management efficiency ratios could be used to measure how well Immunitybio manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 0.89 in 2025, whereas Return On Tangible Assets are likely to drop (1.18) in 2025. At this time, Immunitybio's Non Currrent Assets Other are fairly stable compared to the past year. Other Current Assets is likely to rise to about 25 M in 2025, whereas Total Assets are likely to drop slightly above 299.1 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.70) | (0.67) | |
| Tangible Book Value Per Share | (0.72) | (0.69) | |
| Enterprise Value Over EBITDA | (8.88) | (9.32) | |
| Price Book Value Ratio | (3.66) | (3.47) | |
| Enterprise Value Multiple | (8.88) | (9.32) | |
| Price Fair Value | (3.66) | (3.47) | |
| Enterprise Value | 3.5 B | 2.8 B |
The strategic initiatives led by Immunitybio's management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Beta (0.07) |
Basic technical analysis of Immunitybio Stock
As of the 20th of July, Immunitybio retains the Market Risk Adjusted Performance of 0.0275, downside deviation of 5.39, and Risk Adjusted Performance of 0.018. Immunitybio technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.Immunitybio's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Immunitybio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Immunitybio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Immunitybio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Immunitybio's Outstanding Corporate Bonds
Immunitybio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Immunitybio uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Immunitybio bonds can be classified according to their maturity, which is the date when Immunitybio has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US45258LAA52 Corp BondUS45258LAA52 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Understand Immunitybio's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Immunitybio's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.018 | |||
| Market Risk Adjusted Performance | 0.0275 | |||
| Mean Deviation | 3.61 | |||
| Semi Deviation | 4.9 | |||
| Downside Deviation | 5.39 | |||
| Coefficient Of Variation | 9473.46 | |||
| Standard Deviation | 5.09 | |||
| Variance | 25.86 | |||
| Information Ratio | (0.02) | |||
| Jensen Alpha | (0.28) | |||
| Total Risk Alpha | (0.67) | |||
| Sortino Ratio | (0.02) | |||
| Treynor Ratio | 0.0175 | |||
| Maximum Drawdown | 24.49 | |||
| Value At Risk | (8.62) | |||
| Potential Upside | 8.62 | |||
| Downside Variance | 29.03 | |||
| Semi Variance | 24.0 | |||
| Expected Short fall | (4.02) | |||
| Skewness | (0.21) | |||
| Kurtosis | 1.92 |
| Risk Adjusted Performance | 0.018 | |||
| Market Risk Adjusted Performance | 0.0275 | |||
| Mean Deviation | 3.61 | |||
| Semi Deviation | 4.9 | |||
| Downside Deviation | 5.39 | |||
| Coefficient Of Variation | 9473.46 | |||
| Standard Deviation | 5.09 | |||
| Variance | 25.86 | |||
| Information Ratio | (0.02) | |||
| Jensen Alpha | (0.28) | |||
| Total Risk Alpha | (0.67) | |||
| Sortino Ratio | (0.02) | |||
| Treynor Ratio | 0.0175 | |||
| Maximum Drawdown | 24.49 | |||
| Value At Risk | (8.62) | |||
| Potential Upside | 8.62 | |||
| Downside Variance | 29.03 | |||
| Semi Variance | 24.0 | |||
| Expected Short fall | (4.02) | |||
| Skewness | (0.21) | |||
| Kurtosis | 1.92 |
Consider Immunitybio's intraday indicators
Immunitybio intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Immunitybio stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Immunitybio time-series forecasting models is one of many Immunitybio's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Immunitybio's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Immunitybio Stock media impact
There is far too much social signal, news, headlines, and media speculation about Immunitybio that are available to investors today. This information is accessible both publicly - through Immunitybio's media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Immunitybio-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Immunitybio news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Immunitybio relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Immunitybio's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Immunitybio alpha.
Immunitybio Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Immunitybio can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Immunitybio Historical Investor Sentiment
Investor biases related to Immunitybio's public news can be used to forecast risks associated with an investment in Immunitybio. The trend in average sentiment can be used to explain how an investor holding Immunitybio can time the market purely based on public headlines and social activities around Immunitybio. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Immunitybio's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Immunitybio and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Immunitybio news discussions. The higher the estimate score, the more favorable the investor's outlook on Immunitybio.
Immunitybio Maximum Pain Price Across October 17th 2025 Option Contracts
Immunitybio's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Immunitybio close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Immunitybio's options.
Immunitybio Corporate Management
| Jason JD | General Secretary | Profile | |
| Sandeep MD | Chief Officer | Profile | |
| Helen Luu | Chief Officer | Profile | |
| Leonard MD | Chief Officer | Profile | |
| Jason Liljestrom | General Secretary | Profile | |
| Bruce MD | Senior Affairs | Profile |
Additional Tools for Immunitybio Stock Analysis
When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.